Kefu

Kefu Biotech is a clinical-stage biotechnology company based in Hangzhou, China, specializing in the development of next-generation Adeno-Associated Virus (AAV) gene therapies. The company focuses on addressing high unmet medical needs in central nervous system (CNS) disorders, rare diseases, and ophthalmic conditions. Leveraging its proprietary AAV capsid engineering platform, Kefu Biotech aims to improve tissue specificity and therapeutic efficacy while reducing immunogenicity. Its lead program, KF-01, is an AAV9-based gene therapy for Spinal Muscular Atrophy (SMA) that has advanced into clinical development. The company is also progressing a robust pipeline of candidates for Parkinson's disease and various genetic eye disorders.